黑龙江省调脂药物的临床综合评价

Clinical comprehensive evaluation of lipid-lowering drugs in Heilongjiang Province

目的对调脂药物进行临床综合评价,为临床合理用药及医院目录调整提供参考。方法采用文献研究法、专家调研法和专家论证法建立药品临床综合评价体系,从安全性、有效性、经济性、创新性、适宜性和可及性6个维度对黑龙江省14种调脂药物进行临床综合评价。结果调脂药物临床综合评价体系共涉及6个一级指标,25个二级指标。在安全性和有效性方面,阿托伐他汀(立普妥和安维宁)得分最高;经济性方面,阿托伐他汀(安维宁)、瑞舒伐他汀(爱舒宁)、辛伐他汀(京必舒新)和匹伐他汀(邦之)得分最高;创新性方面,原研品种更占优势;适宜性和可及性方面,阿托伐他汀(立普妥)得分最高。结论黑龙江省14种调脂药物中,阿托伐他汀(立普妥和安维宁)、瑞舒伐他汀(可定)的临床综合评价得分较高,可作为强推荐级别的品种。

Objective To evaluate the lipid-regulating drugs comprehensively and provide a reference for clinical rational use of drugs and adjustment of hospital formulary.Methods A comprehensive clinical evaluation system for drugs was established using literature research,expert research,and expert argumentation.The study encompassed a comprehensive clinical evaluation of 14 lipid-lowering drugs in Heilongjiang Province across six dimensions:safety,effectiveness,economy,innovation,suitability,and accessibility.Results The clinical comprehensive evaluation system for lipid-lowering drugs involves 6 primary indicators and 25 secondary indicators.In terms of safety and efficacy,atorvastatin(Lipitor and Anvinin)scored the highest.In terms of economy,atorvastatin(Anvinin),rosuvastatin(Aisuning),simvastatin(Jingbisuxin),and pivastatin(Bangzhi)scored the highest;In terms of innovation,original research varieties have a greater advantage;atorvastatin(Lipitor)has the highest scores for suitability and accessibility.Conclusion Among the 14 lipid-lowering drugs in Heilongjiang Province,atorvastatin(Lipitor and Anvinin)and rosuvastatin(Keding)have higher comprehensive evaluation scores and are highly recommended varieties.